331 related articles for article (PubMed ID: 12708635)
1. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines.
Brewer HB
Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III19-24. PubMed ID: 12708635
[TBL] [Abstract][Full Text] [Related]
2. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal.
McKenney JM
Pharmacotherapy; 2003 Sep; 23(9 Pt 2):26S-33S. PubMed ID: 14524636
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.
Talbert RL
Am J Manag Care; 2002 Sep; 8(12 Suppl):S301-7. PubMed ID: 12240701
[TBL] [Abstract][Full Text] [Related]
4. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
[TBL] [Abstract][Full Text] [Related]
5. Aggressive lipid management for cardiovascular prevention: evidence from clinical trials.
Friday KE
Exp Biol Med (Maywood); 2003 Jul; 228(7):769-78. PubMed ID: 12876295
[TBL] [Abstract][Full Text] [Related]
6. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
8. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
9. Impact of the new National Cholesterol Education Program (NCEP) guidelines on patient management.
Harmel AP; Berra K
J Am Acad Nurse Pract; 2003 Aug; 15(8):350-60. PubMed ID: 14509100
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
13. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
Ansell BJ; Watson KE; Fogelman AM
JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
15. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
[TBL] [Abstract][Full Text] [Related]
17. Role of the National Cholesterol Education Program Adult treatment panel III guidelines in managing dyslipidemia.
Talbert RL;
Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S3-8; quiz S25. PubMed ID: 12901024
[TBL] [Abstract][Full Text] [Related]
18. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
Bersot TP; Pépin GM; Mahley RW
Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
[TBL] [Abstract][Full Text] [Related]
19. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; ; ;
Circulation; 2004 Jul; 110(2):227-39. PubMed ID: 15249516
[TBL] [Abstract][Full Text] [Related]
20. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
